Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 203.54

+2.2%

12:33 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: psh who wrote (29966)	1/8/2000 3:22:00 PM
From: Henry Niman	Read Replies (1) of 32384

Yes, they are dose related and actually the hypothyroidism is largely restricted to CTCL patients for some reason. The hypothyroidism rarely was seen in other cancer patients. Targretin will be available in 75 mg soft gel tablets and breast cancer prevention was readily demonstrated in the rat model. Prevention, however, may involve the second generation compounds (rexinoids). Some rumors suggest that LLY will soon (maybe at H&Q) announce more than one rexinoid heading for the clinic. They passed on Targretin for diabetes because they wanted to start with the second generation compounds with few side effects. However these compounds have potential applications for some VERY significant markets including PREVENTION of diabetes AND breast cancer and of course LGND owns the lion's share of rights to breast cancer (treatment OR prevention).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next